EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Shares in Cassiopea jumped 76% on the back of phase 3 acne data. Hitting all three co-primary endpoints sets the Swiss biotech up to file for approval of the key pipeline prospect next year. Release

> The French state bank has teamed with Sanofi to create a €100 million ($117 million) biotech fund. Sanofi will contribute €50 million to the fund, which could swell to in size to €250 million if other investors get involved. Reuters

> Transgene secured a deal that will give it a €48 million stake in China’s Tasly Biopharmaceuticals. Statement 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> TxCell licensed a HLA-A2 CAR-Treg program from the University of British Columbia. The chronic transplant rejection program is expected to move into phase 1 next year. Release 

> ReNeuron received $2.5 million from an unidentified U.S. company as a precursor to a possible deal for its retinal stem cell technology and therapeutic programs. Statement 

Suggested Articles

Acceleron’s sotatercept outdid placebo at reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

China’s Biotheus picked up the rights to Tilt Biotherapeutics’ lead oncolytic virus program in greater China.

A Cedars-Sinai team used stem cells to uncover a key mechanism of young onset Parkinson's, as well as a potential remedy—an existing skin treatment.